Cancer Treatment Research (93.395)
Cancer Treatment Research (Assistance Listing 93.395) is run by the National Institutes of Health, part of the Department of Health and Human Services. It awarded $5.6 billion in 3,622 grants from fiscal 2021 to 2025, about $1.5 million per award on average. 47 funding opportunities are open or forecast now.
The typical award was $1.0 million. Half of the 3,622 awards fell between $405,464 and $1.8 million, and they ranged from $0 to $141 million.
- Awarded, FY 2021 to 2025$5.6 billion
- Grant awards3,622
- Typical award$1.0 million
- Awarded in FY 2025$1.3 billion
- Size rank85 of 1824
- Type of assistanceCooperative agreements, project grants
Key findings
- Annual funding rose from $984 million in fiscal 2021 to $1.3 billion in fiscal 2025.
- It is the 85th largest of 1,824 federal grant programs by five-year awards.
- The 20 largest recipients received 41% of the money.
- Awards went to recipients in 50 states and territories.
What the program funds
To develop the means to cure as many cancer patients as possible and to control the disease in those patients who are not cured. Cancer Treatment Research includes the development and evaluation of improved methods of cancer treatment through the support and performance of both fundamental and applied laboratory and clinical research. Research is supported in the discovery, development, and clinical testing of all modes of therapy including: surgery, radiotherapy, chemotherapy, and biological therapy including molecularly targeted therapies, both individually and in combination. In addition, research is carried out in areas of nutritional support, stem cell and bone marrow transplantation, image guided therapies and studies to reduce toxicity of cytotoxic therapies, and other methods of supportive care that may supplement and enhance primary treatment. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to increase private sector commercialization of innovations derived from Federal research and development; to increase small business participation in Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation. Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development; and to foster and encourage participation of socially and economically disadvantaged small business concerns and women-owned small business concerns in technological innovation.
Open opportunities
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (R01 Clinical Trial Optional)
- National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)
- Glioblastoma Therapeutics Network (GTN) (U19 Clinical Trial Required)
- NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)
- NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)
- Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)
- Successor-in-Interest (Type 6 Parent Clinical Trial Optional)
- NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)
- Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)
- Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)
- Toward Translation of Nanotechnology Cancer Interventions (TTNCI; R01 Clinical Trial Not Allowed)
- Molecular Imaging of Inflammation in Cancer (R01 Clinical Trial Not Allowed)
- Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)
- Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)
- Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)
- Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)
- NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)
- NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)
- Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)
Rules from the program listing
Who can apply
The awardee will be a university, college, hospital, public agency, nonprofit research institution, or for-profit organization that submits an application and receives a grant or cooperative agreement for support of research by a named principal investigator. SBIR grants can be awarded only to domestic small businesses (entities that are independently owned, and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees). Primary employment (more than one-half time) of the principal investigator must be with the small business at the time of award and during the conduct of the proposed project. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions. To be eligible for funding, a grant application must be approved for scientific merit and program relevance by a scientific review group and a national advisory council. STTR grants can be awarded only to domestic small business concerns (entities that are independently owned and operated for profit, are not dominant in the field in which research is proposed and have no more than 500 employees) which "partner" with a research institution in cooperative research and development. At least 40 percent of the project is to be performed by the small business concern and at least 30 percent by the research institution. In both Phase I and Phase II, the research must be performed in the U.S. and its possessions.
What the money can and cannot pay for
Grants and cooperative agreements may be made to eligible institutions for the support of cancer research projects. The grants may be used for personnel, consultant costs, equipment, supplies, travel, patient costs, animals, alterations and renovations, miscellaneous items, and indirect costs. SBIR Phase I grants (of approximately 6-months duration) are to establish the technical merit and feasibility of a proposed research effort that may lead to a commercial product or process. Phase II grants are for the continuation of the research initiated in Phase I, and that are likely to result in commercial products or processes. Only Phase I awardees are eligible to receive Phase II support. STTR Phase I grants (normally of 1-year duration) are to determine the scientific, technical, and commercial merit and feasibility of the proposed cooperative effort that has potential for commercial application. Phase II funding is based on results of research initiated in Phase I and scientific and technical merit and commercial potential of Phase II application. The SBIR Fast-Track Initiative provides additional assistance to applicants by expediting the decision and award of SBIR Phase II funding for scientifically meritorious applications for projects that have a high potential for commercialization. Fast-Track is a parallel option whereby Phase I and Phase II projects are reviewed concurrently with the aim of reducing or eliminating the funding gap between Phase I and Phase II.
Matching requirements
This program has no statutory formula. Matching requirements are not applicable to this assistance listing. MOE requirements are not applicable to this assistance listing.
Award range and average, in the agency's words
Range: $5,000 to $22,055,360 Average: $653,665
Funding history and past recipients
From fiscal 2021 to 2025, Cancer Treatment Research (93.395) awarded$5.6 billion across 3,622 grant awards, an average of $1.5 million per award.
Who usually wins
Colleges and universities received 57% of the money, nonprofits 32% and small businesses 8.3%.
| Recipient type | Awards | Amount | Share |
|---|---|---|---|
| Colleges and universities | 2,203 | $3.1 billion | 57% |
| Nonprofits | 850 | $1.8 billion | 32% |
| Small businesses | 441 | $463 million | 8.3% |
| Other | 121 | $136 million | 2.5% |
| State and local governments | 6 | $3.5 million | less than 0.1% |
| Businesses | 1 | $440,287 | less than 0.1% |
By state
44 states have a page for this program: those that received at least $1 million or 10 awards.
| State | Awards | Amount |
|---|---|---|
| California | 477 | $843 million |
| New York | 347 | $604 million |
| Massachusetts | 271 | $568 million |
| Texas | 354 | $442 million |
| Pennsylvania | 230 | $418 million |
| Washington | 117 | $236 million |
| Ohio | 155 | $211 million |
| Illinois | 114 | $193 million |
| North Carolina | 158 | $188 million |
| Minnesota | 90 | $163 million |
| Maryland | 112 | $162 million |
| Florida | 133 | $138 million |
| Virginia | 71 | $128 million |
| Tennessee | 55 | $117 million |
| Michigan | 99 | $117 million |
| Georgia | 96 | $104 million |
| Oregon | 37 | $94.5 million |
| Wisconsin | 46 | $92.7 million |
| Missouri | 75 | $91.6 million |
| Connecticut | 56 | $77.2 million |
| Indiana | 53 | $56.0 million |
| Colorado | 58 | $50.9 million |
| District of Columbia | 27 | $47.2 million |
| New Jersey | 46 | $38.1 million |
| Nebraska | 31 | $37.3 million |
| Alabama | 41 | $36.2 million |
| Kentucky | 35 | $35.3 million |
| South Carolina | 32 | $29.9 million |
| Oklahoma | 20 | $28.9 million |
| Arizona | 26 | $22.7 million |
| Iowa | 16 | $19.7 million |
| New Hampshire | 14 | $18.0 million |
| Utah | 20 | $17.5 million |
| Arkansas | 10 | $13.9 million |
| Maine | 7 | $13.2 million |
| New Mexico | 13 | $13.0 million |
| Louisiana | 15 | $10.0 million |
| Kansas | 11 | $8.2 million |
| Vermont | 3 | $6.9 million |
| Hawaii | 4 | $6.6 million |
| Rhode Island | 12 | $6.4 million |
| West Virginia | 5 | $4.5 million |
| Montana | 1 | $2.4 million |
| Delaware | 2 | $2.4 million |
| Alaska | 1 | $441,796 |
| Idaho | 1 | $395,418 |
| Nevada | 1 | $362,531 |
| Wyoming | 1 | $345,409 |
| North Dakota | 1 | $189,634 |
| South Dakota | 1 | $145,081 |